Zobrazeno 1 - 3
of 3
pro vyhledávání: '"João Pedro Homse-Netto"'
Autor:
João Pedro Homse-Netto, Luiza Aleixo-Fadul, João Antonio Soler, Fabio Leite-Couto- Fernandez, Daniel Vilarim Araujo
Publikováno v:
Brazilian Journal of Oncology, Vol 19 (2023)
Introduction: Abiraterone acetate is widely used for the treatment of prostate cancer. In Brazil, the label dose is not affordable to most patients due to its elevated cost. Mounting data supports the efficacy of abiraterone acetate low-dose with foo
Externí odkaz:
https://doaj.org/article/54529d93847142baab6ada0ab8db61cd
Autor:
João Pedro Homse Netto, João Pedro Sant'Anna Pinheiro, Mariana Lopes Ferrari, Mirella Tizziani Soares, Rogério Augusto Gomes Silveira, Mariana Espiga Maioli, Vinicius Daher Alvares Delfino
Publikováno v:
Brazilian Journal of Nephrology, Iss 0 (2018)
ABSTRACT Introduction: The incidence of gastrointestinal disorders among patients with chronic kidney disease (CKD) is high, despite the lack of a good correlation between endoscopic findings and symptoms. Many services thus perform upper gastrointes
Externí odkaz:
https://doaj.org/article/669060cfb35b4bd993f46149a7e37000
Autor:
Iza Andrade de A. Souza, Beatriz de M. Dobbert, Barbara G. Sao Jose, Joao Pedro Homse-Netto, Larissa L. Furlan, Maira S. Abreu, Camila Ferrari, Bruno Uchoa, Kathia Abdallah, Stephano N. Lucio, Joao A. Soler, Fabio L.C. Fernandez, Luiza Ferreira, Joao D. Guedes, Aline F. Fares, Daniel V. Araujo
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSEMounting data suggest that lower doses of anti-PD(L)1 agents can be as efficacious as label-approved doses at a fraction of its cost. We compare the outcomes of patients treated with low-dose (LD) and with conventional-dose (CD) anti-PD(L)1 ag
Externí odkaz:
https://doaj.org/article/b1d064690de94f7a891e06ea352b2951